Press release
Masimo to Report First Quarter 2021 Financial Results after Market Close on Tuesday, April 27
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) will release first quarter 2021
About this update from Masimo Corporation
[{"type":"text","content":"\nConference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)\n\n IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI) will release first quarter 2021 financial results for the period ended April 3, 2021, after the market closes on Tuesday, April 27, 2021. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.\n\nTo register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID number. Reminders about the call will also be sent to registered participants via email.\n\nConference Call Registration Link:\n\nhttp://www.directeventreg.com/registration/event/4934128\n\nA replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.\n\nAbout Masimo\n\nMasimo (Nasdaq: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll. Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET™ sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values...